You might be surprised that I've put COVID-19 first on this list. Pfizer's sinking revenue, profits, and share price over the last few years have been primarily caused by the steep sales decline for ...

It is definitely a strong contender.

Pfizer draws attention as healthcare steadies a mixed market, supported by oncology progress, vaccine development and defensive demand.

Pfizer reported third-quarter revenue and adjusted profit that blew past expectations. The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales. It ...

Pfizers approaching patent cliff and expanding pipeline remain central as the pharmaceutical group advances oncology programs ...

Pfizer’s PFE fourth-quarter results were strong as it beat estimates for earnings as well as sales. Adjusted earnings per share of 63 cents were much higher than 10 cents in the year-ago quarter.